Sackler family reaped roughly $13 billion from Oxycontin-maker Purdue


by   |  VIEW 195
Sackler family reaped roughly $13 billion from Oxycontin-maker Purdue

On Friday, the 4th of October 2019, several US State attorneys, opposing an attempt to settle a deal with Oxycontin-maker Perdue Pharma LP, owned by a wealthy Sackler family, which would make the Sackler family immune to allegations that the Purdue Pharma LP had helped fuel up a nationwide opioid epidemic crisis, had claimed that the opioid-painkiller Oxycontin-maker Purdue Pharma LP might have tilted more than $13 billion to the company’s controlling stakeholder Sackler family in profits.

In point of fact, latest accusations of state Attorney Generals were brought into light after the US-based drugmaker had proceeded with a bankruptcy filing this week, while a settlement deal alongside an allowance of a timeframe to reorganize the company would immune it and its stakeholders from thousands of lawsuits filed across the United States seeking liabilities from mischievous marketing of Purdue Pharma LP that had undermined the abuse potentiality of its opioid painkiller, Oxycontin.

Meanwhile, according to a court document seen by a press agency reporter on Friday (October 4th), Purdue Pharma LP had not filed an exact timeframe or amount of the illegal transactions which it made to the Sackler family, however a company executive had testified earlier that the Pharmaceutical company had transferred between $12 to $13 billion to the Sacklers that would likely to heighten the settlement cost further, as Sacklers had previously declined to lay off more than $3 billion in liabilities to settle the nationwide lawsuits, suggested analysts.